Proteases (Aspartate)

Proteases (Aspartate)

Proteases, also known as proteolytic enzymes, are enzymes that catalyze the breakdown of proteins by hydrolysis of peptide bonds. By cleaving proteins, proteases are involved in the control of a large number of key physiological processes such as cell-cycle progression, cell proliferation and cell death, DNA replication, tissue remodeling, haemostasis (coagulation), wound healing and the immune response. So far, inappropriate proteolysis has been found to have a major role in cancer as well as cardiovascular, inflammatory, neurodegenerative, bacterial, viral and parasitic diseases. Because excessive proteolysis can be prevented by blocking the appropriate proteases, this area is widely explored by pharmaceutical companies. Their mechanism of action classifies the large family of proteases as either serine, cysteine or threonine proteases (amino-terminal nucleophile hydrolases), or as aspartic, metallo and glutamic proteases (with glutamic proteases being the only subtype not found in mammals so far). Interestingly, the serine and cysteine proteases act directly as nucleophiles to attack the substrate (by generating covalent acyl enzyme intermediates). On the other hand, the aspartyl and zinc proteases activate water molecules as the direct attacking species on the peptide bond. Proteases of the different classes can be further grouped into families on the basis of amino acid sequence comparison, and families can be assembled into clans based on similarities in their three-dimensional structures.Five subfamilies of aspartic proteases (EC 3.4.23.-) are classified, all sharing a highly conserved sequence of Asp-Thr-Gly. Compared to the three other types of proteases, serine, cysteine, and metalloproteases, aspartic proteases comprise a relatively small group. The aspartic proteases of many pathogens represent attractive targets for inhibitor design to control the progression of these diseases. The development of effective HIV protease inhibitor drugs for the treatment of HIV infection in AIDS illustrates the importance of this approach. Most of the aspartic proteases belong to a pepsin structural superfamily, having homologous primary and tertiary structures and nearly identical catalytic apparatus.

Read More
sort-descending
  • BACE-1 Inhibitor
    1125
    The price depends on the options chosen on the product page

    From $121.00

  • BMS 232632
    1441
    The price depends on the options chosen on the product page

    From $88.00

  • DAPT
    1484
    The price depends on the options chosen on the product page

    From $99.00

  • γ-Secretase Inhibitor BZ
    1487
    The price depends on the options chosen on the product page

    From $99.00

  • γ-Secretase Inhibitor DBZ
    1488
    The price depends on the options chosen on the product page

    From $88.00

  • Nelfinavir mesylate
    1553
    The price depends on the options chosen on the product page

    From $99.00

  • Compound 120
    1753
    The price depends on the options chosen on the product page

    From $132.00

  • LY 2886721 hydrochloride
    1964
    The price depends on the options chosen on the product page

    From $115.50

  • Begacestat
    2117
    The price depends on the options chosen on the product page

    From $93.50

  • LY 2811376
    2225
    The price depends on the options chosen on the product page

    From $137.50

  • RO 4929097
    2521
    The price depends on the options chosen on the product page

    From $148.50

  • LX2343
    2869
    The price depends on the options chosen on the product page

    From $137.50

  • BACE-2 Inhibitor
    2957
    The price depends on the options chosen on the product page

    From $154.00

  • Darunavir
    3137
    The price depends on the options chosen on the product page

    From $66.00

  • Lopinavir
    3138
    The price depends on the options chosen on the product page

    From $88.00

Items 1-15 of 19

More About Proteases (Aspartate)

Proteases, also known as proteolytic enzymes, are enzymes that catalyze the breakdown of proteins by hydrolysis of peptide bonds. By cleaving proteins, proteases are involved in the control of a large number of key physiological processes such as cell-cycle progression, cell proliferation and cell death, DNA replication, tissue remodeling, haemostasis (coagulation), wound healing and the immune response. So far, inappropriate proteolysis has been found to have a major role in cancer as well as cardiovascularinflammatoryneurodegenerativebacterial, viral and parasitic diseases. Because excessive proteolysis can be prevented by blocking the appropriate proteases, this area is widely explored by pharmaceutical companies. Their mechanism of action classifies the large family of proteases as either serinecysteine or threonine proteases (amino-terminal nucleophile hydrolases), or as asparticmetallo and glutamic proteases (with glutamic proteases being the only subtype not found in mammals so far)[1]. Interestingly, the serine and cysteine proteases act directly as nucleophiles to attack the substrate (by generating covalent acyl enzyme intermediates). On the other hand, the aspartyl and zinc proteases activate water molecules as the direct attacking species on the peptide bond. Proteases of the different classes can be further grouped into families on the basis of amino acid sequence comparison, and families can be assembled into clans based on similarities in their three-dimensional structures[2].
Five subfamilies of aspartic proteases (EC 3.4.23.-) are classified, all sharing a highly conserved sequence of Asp-Thr-Gly. Compared to the three other types of proteases, serine, cysteine, and metalloproteases, aspartic proteases comprise a relatively small group. The aspartic proteases of many pathogens represent attractive targets for inhibitor design to control the progression of these diseases. The development of effective HIV protease inhibitor drugs for the treatment of HIV infection in AIDS illustrates the importance of this approach. Most of the aspartic proteases belong to a pepsin structural superfamily, having homologous primary and tertiary structures and nearly identical catalytic apparatus[3].


[1] Targeting proteases: successes, failures and future prospects. Boris Turk. Nature Reviews – Drug Discovery. Volume 5, 2006, 785-799.
[2] Proteases: Multifunctional Enzymes in Life and Disease. C. López-Otín, J.S. Bond. J. Biol. Chem. 2008, 283, 30433-30437.
[3] R. Mannhold, H. Kubinyi, G. Folkers (Editors). Aspartic Acid Proteases as Therapeutic Targets. Methods and Principles in Medicinal Chemistry..  2010. Wiley-VCH Verlag GmbH & Co. KGaA. ISBN: 9783527318117.

Loading...